Khan Samina's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed Mar 6, 2023
- Accession no.
- 0001209191-23-016306
- Filed
- Mar 6, 2023
- Trade date
- Mar 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.37M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Khan SaminaCIK 0001903865 | Officer (SVP, Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A common stock | MOption exerciseAcquired | +25,000 | $27.32 | +$683,000 | 71,905 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −3,395 | $83.70 | −$284,161.5 | 68,510 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −18,956 | $85.02 | −$1,611,639.12 | 49,554 | Direct | |
| Mar 2, 2023 | Class A common stock | SSaleDisposed | −2,649 | $85.38 | −$226,171.62 | 46,905 | Direct | |
| Mar 3, 2023 | Class A common stock | SSaleDisposed | −2,813 | $87.36 | −$245,743.68 | 44,092 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A common stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 25,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.